SCHEMBL7035477

SCHEMBL7035477

NC(=O)n1c(=O)n(Cc2ccccc2)c(=O)c2sc(C(=O)OCc3ccccc3)cc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.51
KMT2A Q03164 6/20 0.39
GAA P10253 3/20 0.39
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 2/20 0.39
KDM4E B2RXH2 2/20 0.39
HTT P42858 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
MEN1 O00255 4/20 0.38
ALDH1A1 P00352 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PLA2G2A P14555 2/20 0.37
TSHR P16473 2/20 0.37
HSD17B10 Q99714 1/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A3 Q01959 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
GLA P06280 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7032058 0.85 MMP13 (0.53) MMP13KMT2ALMNASMN1; SMN2KDM4E
SCHEMBL7034915 0.83 MMP13 (0.51) MMP13KMT2ASMN1; SMN2KDM4EMEN1
SCHEMBL7032054 0.76 MMP13 (0.52) MMP13KMT2ALMNASMN1; SMN2MAPT
SCHEMBL7100082 0.74 HDAC6 (0.48) MMP13KMT2ALMNASMN1; SMN2MAPT
SCHEMBL7033357 0.74 SMN1; SMN2 (0.54) MMP13KMT2AGAALMNASMN1; SMN2
SCHEMBL7104309 0.73 GAA (0.45) MMP13KMT2AGAALMNAMAPT
SCHEMBL6252686 0.72 MMP13 (0.53) MMP13KMT2ALMNASMN1; SMN2MAPT
SCHEMBL7098165 0.72 HDAC1 (0.47) KMT2AGAALMNASMN1; SMN2HTT
SCHEMBL6258644 0.72 MMP13 (0.54) MMP13KMT2AGAALMNASMN1; SMN2
SCHEMBL6473100 0.72 MMP13 (0.52) MMP13KMT2AGAALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370562-A1 THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2003-12-17 EP disclosed
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors HARTER WILLIAM GLEN (US) 2003-01-02 US disclosed
WO-2002064598-A1 THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors MMP13, MMP3, MMP25 MMP13 1/4885KMT2A 1976/4885GAA 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.